$170 Million is the total value of Casdin Capital, LLC's 29 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 35.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SAGE | Sell | SAGE THERAPEUTICS INC | $18,123,000 | +36.8% | 255,000 | -1.7% | 10.69% | -2.3% |
| FMI | Sell | FOUNDATION MEDICINE INC | $15,480,000 | +60.2% | 480,000 | -12.1% | 9.13% | +14.4% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $13,870,000 | +38.2% | 237,500 | -1.2% | 8.18% | -1.3% |
| EVH | Sell | EVOLENT HEALTH INCcl a | $11,596,000 | +41.2% | 520,000 | -6.3% | 6.84% | +0.8% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $5,128,000 | -17.8% | 400,000 | -21.6% | 3.02% | -41.3% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $3,740,000 | -14.9% | 101,500 | -66.6% | 2.21% | -39.2% |
| KITE | Sell | KITE PHARMA INC | $3,336,000 | -20.9% | 42,500 | -54.8% | 1.97% | -43.5% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $2,819,000 | -11.4% | 55,000 | -35.3% | 1.66% | -36.7% |
| BLUE | Sell | BLUEBIRD BIO INC | $2,318,000 | -54.5% | 25,500 | -69.1% | 1.37% | -67.5% |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -12,500 | -100.0% | -0.74% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -45,000 | -100.0% | -0.95% | – |
| GNMX | Exit | AEVI GENOMIC MEDICINE INC | $0 | – | -375,000 | -100.0% | -1.60% | – |
| CERN | Exit | CERNER CORP | $0 | – | -65,000 | -100.0% | -2.54% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -25,000 | -100.0% | -2.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-31 |
| 4 | 2024-05-28 |
| 4 | 2024-05-28 |
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.